United Therapeutics Corporation · UTHR · FY2026 Q3 · Calendar Q4 2026

United Therapeutics’ record quarter highlights Tyvaso growth and pipeline execution

The supplied call analysis points to commercial momentum in Tyvaso and a broader pipeline as the main supports for United Therapeutics’ outlook. That case is balanced by a delayed soft-mist inhaler filing and execution risks tied to regulatory, manufacturing, and patient-switch dynamics.

Reported Before market openNASDAQHealthcare $25.79B market cap
80quality score

Earnings scorecard

Reported versus consensus
Reported EPS — Consensus $6.01
EPS surprise — Reported versus consensus
Reported revenue — Consensus $781.1M
Revenue surprise — Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +0.6% Event window
SPY move +1.9% Same window
Abnormal move -1.4% Stock minus SPY
Volume 0.7× Versus trailing sessions
Subsequent drift 0.0% Up to 20 sessions
UTHRSPY benchmark

Ask FN2 about UTHR FY2026 Q3

Transcript, numbers and history already loaded
What drove UTHR's +0.6% move after FY2026 Q3 earnings?What changed in UTHR's guidance and outlook in FY2026 Q3?Give me the bull and bear case for UTHR after FY2026 Q3 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior-quarter analysis, the current call analysis describes record Q3 revenue and Tyvaso sales, and reports a favorable Liquidia settlement that clarified the YUTREPIA label and marketing landscape. It also identifies a 2027 soft-mist inhaler NDA filing timeline after additional data requirements; the prior-quarter analysis had described stronger second-half performance and launch opportunities but did not mention that delay.

Guidance delta

No formal guidance was provided in the current call analysis. Prior-quarter guidance sentiment was described as maintained, so the supplied material does not establish a numerical or directional guidance change.

Key takeaways

  • Tyvaso was the principal commercial growth driver in the supplied Q3 call analysis, alongside higher-dose cartridges and expanded sales-force activity.
  • Management highlighted pipeline opportunities including nebulized Tyvaso for IPF and ralinepag for PAH.
  • A favorable Liquidia settlement clarified label and promotion constraints, according to the call analysis.
  • The soft-mist inhaler NDA timeline moved to 2027, with additional data collection cited.
  • The supplied event facts do not include actual-versus-consensus EPS or revenue results.

Management priorities

  • Maintain physician engagement and commercial execution for Tyvaso and related products.
  • Advance nebulized Tyvaso for IPF and ralinepag programs through their stated regulatory and development paths.
  • Collect additional data for the soft-mist inhaler program and continue development of the broader pipeline.
  • Address supplier compliance and manufacturing contingencies relevant to ralinepag.

Follow UTHR with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Company context

Snapshot as of publication

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH.…

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
MDLN Medline Inc. FY2026 Q3 · Calendar Q4 2026 — +16.2% Medline Raises 2026 Organic Sales Outlook on 10% Q3 Growth
NVO Novo Nordisk A/S FY2026 Q3 · Calendar Q4 2026 — +6.4% Novo Nordisk Q3: obesity demand supports growth, pricing and LOE remain risks
CRL Charles River Laboratories International, Inc. FY2026 Q3 · Calendar Q4 2026 — -6.0% Charles River raises FY2026 outlook after strong Q3; demand and margins improve
AMGN Amgen Inc. FY2026 Q3 · Calendar Q4 2026 +11.4% +1.6% Amgen Q3: Growth Drivers, Pipeline Progress and Higher 2026 Guidance
BNTX BioNTech SE FY2026 Q3 · Calendar Q4 2026 +168.2% -0.7% BioNTech lifts 2026 revenue outlook as oncology pipeline advances
PFE Pfizer Inc. FY2026 Q3 · Calendar Q4 2026 +18.4% -2.2% Pfizer raises 2026 revenue outlook as acquired portfolio expands

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the UTHR recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-11-04T18:07:37.644569+00:00
  2. FN2 earnings calendar · 2026-11-04T01:23:13.345574+00:00
  3. Polygon adjusted daily market bars · 2026-11-04T18:20:47.363240+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-04T18:20:47.360542+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-04. For educational purposes only; not investment advice.